{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T16:27:22Z","timestamp":1794587242539,"version":"4.9.1"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"25","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,19]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>There are limited data on the impact of coronavirus disease 2019 (COVID-19) vaccines on mortality among people living with human immunodeficiency virus (HIV) (PLHIV) across different severe acute respiratory syndrome coronavirus 2 variants. We assessed the impact of the COVID-19 vaccine in reducing in-hospital mortality among PLHIV across various severe acute respiratory syndrome coronavirus 2 variant waves. We analyzed individual-level data from 159,150 patients hospitalized with COVID-19 across 43 countries. Flexible parametric survival models were used to estimate the association between COVID-19 vaccination and in-hospital mortality, accounting for HIV status. Among HIV-negative individuals, COVID-19 vaccination reduced the risk of in-hospital mortality by 38 to 42% across all variant waves compared to their unvaccinated counterparts. In PLHIV, the protective effect of vaccination was less pronounced. Vaccinated PLHIV exhibited higher mortality risks compared to unvaccinated HIV-negative individuals: 41% higher during the Omicron wave (adjusted hazard ratio [aHR] 1.41, 95% confidence interval [CI] 1.05\u20131.89) and no significant difference during the pre-Delta and Delta waves. However, vaccinated PLHIV consistently showed lower mortality risks than unvaccinated PLHIV, with mortality reductions of 60% (aHR 0.40, 95% CI 0.31\u20130.51) during the pre-Delta period, 50% during Delta (aHR 0.50, 95% CI 0.33\u20130.75), and 54% during Omicron (aHR 0.46, 95% CI 0.36\u20130.59). While COVID-19 vaccination significantly reduced inpatient mortality among PLHIV, mortality risks remained elevated compared to HIV-negative individuals, particularly during the Omicron variant wave. Overall, vaccination still offered substantial protection against death for PLHIV compared to unvaccinated PLHIV. These findings underscore the need for targeted vaccination strategies, including booster doses, to protect high-risk populations such as PLHIV, in alignment with World Health Organization recommendations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000049386","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T06:00:06Z","timestamp":1782108006000},"page":"e49386","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Vaccine effectiveness against COVID-19 in-hospital mortality in people living with HIV across SARS-CoV-2 variant waves: Analyses of data from the WHO Global Clinical Platform"],"prefix":"10.1097","volume":"105","author":[{"given":"Seth","family":"Inzaule","sequence":"first","affiliation":[{"name":"Department of Global Health, Amsterdam UMC, Amsterdam Institute for Global Health and Development, University of Amsterdam, Amsterdam, North Holland, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronaldo","family":"Silva","sequence":"additional","affiliation":[{"name":"UNDP\/UNFPA\/UNICEF\/WHO\/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), Department of Sexual and Reproductive Health and Research, World Health Organization, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Ford","sequence":"additional","affiliation":[{"name":"Department of Global HIV, STI, Hepatitis Programmes, World Health Organization, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soe Soe","family":"Thwin","sequence":"additional","affiliation":[{"name":"UNDP\/UNFPA\/UNICEF\/WHO\/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), Department of Sexual and Reproductive Health and Research, World Health Organization, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jassat","family":"Waasila","sequence":"additional","affiliation":[{"name":"National Institute for Communicable Diseases, Johannesburg, Gauteng, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alimuddin","family":"Zumla","sequence":"additional","affiliation":[{"name":"Division of Infection and Immunity, Center for Clinical Microbiology, University College London, London, UK"},{"name":"NIHR Biomedical Research Centre, UCL Hospitals NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meg","family":"Doherty","sequence":"additional","affiliation":[{"name":"Department of Global HIV, STI, Hepatitis Programmes, World Health Organization, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Diaz","sequence":"additional","affiliation":[{"name":"Department of Country Readiness Strengthening, Health Emergencies Programme, World Health Organization, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8416-2581","authenticated-orcid":false,"given":"Silvia","family":"Bertagnolio","sequence":"additional","affiliation":[{"name":"Department of Antimicrobial Resistance, World Health Organization, Geneva, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261113","doi-asserted-by":"crossref","first-page":"e486","DOI":"10.1016\/S2352-3018(22)00097-2","article-title":"Clinical features of, and risk factors for, severe or fatal COVID-19 among people living with HIV admitted to hospital: analysis of data from the WHO global clinical platform of COVID-19.","volume":"9","author":"Bertagnolio","year":"2022","journal-title":"Lancet HIV"},{"key":"R2-20261113","doi-asserted-by":"crossref","first-page":"6283","DOI":"10.1038\/s41598-021-85359-3","article-title":"Epidemiology and outcomes of COVID-19 in HIV-infected individuals: a systematic review and meta-analysis.","volume":"11","author":"Ssentongo","year":"2021","journal-title":"Sci Rep"},{"key":"R4-20261113","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1136\/bmj.p2975","article-title":"Covid-19: WHO adds JN.1 as new variant of interest.","volume":"383","author":"Looi","year":"2023","journal-title":"BMJ"},{"key":"R5-20261113","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine.","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"R6-20261113","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine.","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"R7-20261113","doi-asserted-by":"crossref","first-page":"5585","DOI":"10.1016\/j.vaccine.2014.07.101","article-title":"Influenza vaccination in HIV-infected individuals: systematic review and assessment of quality of evidence related to vaccine efficacy, effectiveness and safety.","volume":"32","author":"Remschmidt","year":"2014","journal-title":"Vaccine"},{"key":"R8-20261113","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.virol.2009.11.003","article-title":"Loss of HIV-specific memory B-cells as a potential mechanism for the dysfunction of the humoral immune response against HIV.","volume":"397","author":"Bussmann","year":"2010","journal-title":"Virology"},{"key":"R9-20261113","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0140-6736(14)60164-1","article-title":"HIV infection: epidemiology, pathogenesis, treatment, and prevention.","volume":"384","author":"Maartens","year":"2014","journal-title":"Lancet"},{"key":"R10-20261113","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/cid\/cit937","article-title":"Long-term immune responses to vaccination in HIV-infected patients: a systematic review and meta-analysis.","volume":"58","author":"Kern\u00e9is","year":"2014","journal-title":"Clin Infect Dis"},{"key":"R11-20261113","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.3390\/v15091844","article-title":"Immunogenicity and efficacy of vaccination in people living with human immunodeficiency virus.","volume":"15","author":"Tortellini","year":"2023","journal-title":"Viruses"},{"key":"R12-20261113","doi-asserted-by":"crossref","first-page":"101360","DOI":"10.1016\/j.eclinm.2022.101360","article-title":"Sputnik V protection from COVID-19 in people living with HIV under antiretroviral therapy.","volume":"46","author":"Gushchin","year":"2022","journal-title":"EClinicalMedicine"},{"key":"R13-20261113","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ijid.2022.11.035","article-title":"Effectiveness of COVID-19 vaccines in people living with HIV in British Columbia and comparisons with a matched HIV-negative cohort: a test-negative design.","volume":"127","author":"Fowokan","year":"2023","journal-title":"Int J Infect Dis"},{"key":"R14-20261113","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0140-6736(22)00007-1","article-title":"Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study.","volume":"399","author":"Bekker","year":"2022","journal-title":"Lancet"},{"key":"R15-20261113","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1056\/NEJMc2119236","article-title":"SARS-CoV-2 omicron variant neutralization in serum from vaccinated and convalescent persons.","volume":"386","author":"R\u00f6ssler","year":"2022","journal-title":"N Engl J Med"},{"key":"R16-20261113","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/S1473-3099(22)00524-2","article-title":"Evasion of neutralising antibodies by omicron sublineage BA.2.75.","volume":"22","author":"Sheward","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"R18-20261113","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.3390\/vaccines10091569","article-title":"Immunogenicity and safety of COVID-19 vaccines among people living with HIV: a systematic review and meta-analysis.","volume":"10","author":"Kang","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"R19-20261113","doi-asserted-by":"crossref","first-page":"e916","DOI":"10.1093\/cid\/ciab1009","article-title":"Differences in post-mRNA vaccination severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulin G (IgG) concentrations and surrogate virus neutralization test response by human immunodeficiency virus (HIV) status and type of vaccine: A M.","volume":"75","author":"Spinelli","year":"2022","journal-title":"Clin Infect Dis"},{"key":"R20-20261113","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3390\/v14020277","article-title":"Comparing immune responses to inactivated vaccines against SARS-CoV-2 between people living with HIV and HIV-negative individuals: a cross-sectional study in China.","volume":"14","author":"Huang","year":"2022","journal-title":"Viruses"},{"key":"R21-20261113","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41586-022-04399-5","article-title":"Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron.","volume":"602","author":"Carre\u00f1o","year":"2022","journal-title":"Nature"},{"key":"R22-20261113","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/s41586-021-04085-y","article-title":"Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity.","volume":"600","author":"Lucas","year":"2021","journal-title":"Nature"},{"key":"R23-20261113","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s15010-021-01721-7","article-title":"Humoral response to SARS-CoV-2 vaccines in people living with HIV.","volume":"50","author":"Noe","year":"2022","journal-title":"Infection"},{"key":"R24-20261113","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41541-022-00452-6","article-title":"Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy.","volume":"7","author":"Brumme","year":"2022","journal-title":"npj Vaccines"},{"key":"R25-20261113","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1097\/QAD.0000000000003237","article-title":"Surrogate neutralization responses following severe acute respiratory syndrome coronavirus 2 vaccination in people with HIV: comparison between inactivated and mRNA vaccine.","volume":"36","author":"Wong","year":"2022","journal-title":"AIDS"},{"key":"R26-20261113","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1016\/j.cmi.2022.05.018","article-title":"Severe immunosuppression is related to poorer immunogenicity to SARS-CoV-2 vaccines among people living with HIV.","volume":"28","author":"Corma-G\u00f3mez","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"R27-20261113","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1093\/infdis\/jiac229","article-title":"People with human immunodeficiency virus receiving suppressive antiretroviral therapy show typical antibody durability after dual coronavirus disease 2019 vaccination and strong third dose responses.","volume":"227","author":"Lapointe","year":"2023","journal-title":"J Infect Dis"},{"key":"R28-20261113","doi-asserted-by":"crossref","first-page":"77","DOI":"10.15585\/mmwr.mm7304a2","article-title":"Early estimates of updated 2023-2024 (Monovalent XBB.1.5) COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infection attributable to co-circulating omicron variants among immunocompetent adults - increasing community access to testing progra.","volume":"73","author":"Link-Gelles","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R29-20261113","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/QAD.0000000000003751","article-title":"Bridging the Gap: identifying factors impacting mRNA SARS-CoV-2 vaccine booster response in people living with HIV-1.","volume":"38","author":"Chammartin","year":"2023","journal-title":"AIDS"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049386","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T16:00:13Z","timestamp":1794585613000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":27,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000049386","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"assertion":[{"value":"2025-11-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}